T-DXd yields superior outcomes over chemotherapy-based regimens in patients previously treated with T-DM1
SAN ANTONIO – Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the ...
